MINUTE Medical Vienna

MINUTE Medical is a unique private medical center focused on innovative methods for diagnosing and treating oncological diseases. It is a specialized outpatient center in Vienna dedicated to modern nuclear medicine, molecular imaging, and theranostic approaches in oncology. Rather than functioning as a conventional inpatient hospital, the center is designed around ambulatory cancer care, allowing patients to receive highly specialized nuclear medicine procedures without prolonged hospitalization. In particular, doctors use molecular internal radionuclide therapy for metastatic prostate cancer, neuroendocrine tumors, and bone metastases. The clinic is located in the very center of Austria, near the Donaukanal, and charms with its modern, futuristic interior. Patients can undergo all necessary treatments and high-quality diagnostics at a single institution, with the utmost comfort. Outpatient treatment allows the client to avoid being tied to a hospital bed and to rest in a home environment. A defining feature of MINUTE Medical is its focus on the theranostic principle, in which molecular imaging is used not only to visualize disease but also to determine whether a patient is likely to benefit from a corresponding targeted treatment. This approach creates a close connection between diagnosis and therapy and is particularly relevant when treatment decisions depend on the biological characteristics of an individual tumor. The center specializes in oncological theranostics, with a particular focus on prostate cancer and neuroendocrine malignancies. Each patient undergoes a detailed diagnosis, which determines the effectiveness of one method over another even before treatment begins. PSMA-, FAPI-, and DOTA-TATE-based positron emission tomography (PET/CT) are among the world's most accurate diagnostic modalities and are actively used at Vienna MINUTE Medical. Thanks to the detection of surface markers and specific tumor proteins, these technologies enable the identification of malignant lesions at the smallest size. The presence of PSMA, somatostatin receptor, and fibroblast activation protein markers in tumors is crucial in assessing therapeutic success. Based on research and many years of experience, the medical center uses radionuclide therapy with labeled ligands, Lutetium-177 [177Lu] or Actinium-225 [225Ac], for the targeted treatment of prostate cancer. Thanks to the molecular delivery of radiopharmaceuticals through PSMA enzymes, the surrounding organs and tissues are protected. If all recommendations are followed, short sessions with intravenous access lasting 20 minutes are well tolerated and rarely cause temporary side effects. Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE is an intravenous treatment that preserves surrounding organs by damaging healthy tissue by only 0. 3 mm. PRRT is relevant for neuroendocrine tumors, most commonly found in the gastrointestinal tract, lung, adrenal, and pancreas. After therapy, you can leave the clinic with minimal precautions. Therapy for bone metastases with radium-223 dichloride (Xofigo) is one of the most common treatments for osteoblastic bone metastases. The technique has numerous benefits, particularly in significantly relieving pain symptoms by destroying osteoblasts. Another distinctive aspect is the center's investment in radiopharmaceutical production. MINUTE Medical works with specialists in radiopharmaceutical chemistry and has developed in-house capabilities for radioligand synthesis. This infrastructure is particularly important for advanced theranostics because radiopharmaceuticals have complex production, quality control, and handling requirements and must be prepared in accordance with strict nuclear medicine standards. MINUTE Medical also has a strong connection with academic nuclear medicine and clinical research. Its specialists have contributed to scientific work on prostate cancer imaging, radioligand therapy, treatment response, and the safety of radionuclide approaches across diverse patient populations. Research published through the center has, for example, examined Lu-177 PSMA therapy in octogenarian patients with metastatic castration-resistant prostate cancer, supporting its use even in an elderly population when patients are appropriately selected. The medical center also benefits from the expertise of Prof. Dr. Markus Hartenbach, whose professional work focuses on prostate cancer theranostics, nuclear medicine, and radiation protection. His career includes academic work at the Medical University of Vienna and recognition for research achievements in nuclear medicine, including awards from professional societies in Germany and Austria. For international patients, the outpatient format can be particularly practical. Instead of organizing a lengthy hospital admission, treatment can be structured around scheduled visits, medical monitoring, and discharge after the appropriate radiation-safety assessment. This makes it possible to combine specialized oncological care in Vienna with accommodation outside the medical facility when clinically appropriate. MINUTE Medical in Vienna offers minimally invasive cancer treatment, which has a higher success rate than standard treatments. The significance and importance of the clinic's treatment methods do not imply a problematic rehabilitation period or severe side effects. Comfortable conditions, short session durations, and doctors' professionalism are among the essential advantages for every patient.